Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 3/20 | 1.00 |
| ▸ | ABL1 | P00519 | 17/20 | 0.72 |
| ▸ | KIT | P10721 | 1/20 | 0.66 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21859613 | 0.85 | MAP4K1 (0.83) | MAP4K1ABL1KITPDGFRA | |
| SCHEMBL29466397 | 0.85 | MAP4K1 (0.83) | MAP4K1ABL1KITPDGFRA | |
| SCHEMBL10287891 | 0.83 | ABL1 (1.00) | ABL1 | |
| SCHEMBL21859616 | 0.82 | MAP4K1 (0.78) | MAP4K1ABL1KITPDGFRA | |
| SCHEMBL29466390 | 0.82 | MAP4K1 (0.78) | MAP4K1ABL1KITPDGFRA | |
| SCHEMBL21859612 | 0.82 | MAP4K1 (1.00) | MAP4K1ABL1KITPDGFRA | |
| SCHEMBL29466369 | 0.82 | MAP4K1 (1.00) | MAP4K1ABL1KITPDGFRA | |
| SCHEMBL20948271 | 0.82 | ABL1 (0.69) | MAP4K1ABL1 | |
| SCHEMBL30418736 | 0.80 | ABL1 (1.00) | ABL1KITPDGFRA | |
| SCHEMBL20855224 | 0.80 | ABL1 (1.00) | ABL1KITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368170-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20220073520-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| WO-2020069402-A1 | CINNOLINE COMPOUNDS AND FOR THE TREATMENT OF HPK1-DEPENDENT DISORDERS SUCH AS CANCER | GENENTECH, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368170-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | HIPK1, CDC7, MAP3K7 | MAP4K1 40/4885ABL1 690/4885KIT 182/4885 |
| US-20220073520-A1 | CINNOLINE COMPOUNDS AND USES THEREOF | HIPK1, CDC7, MAP3K7 | MAP4K1 40/4885ABL1 690/4885KIT 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.